Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness

EUnetHTA methodological guideline The guidance document reflects the current international status of information retrieval science. Although focused on information retrieval in regard to the effectiveness of a health technology, a majority of recommended procedures and methods are generally applicable to the information retrieval and literature searching in HTA. To be helpful for practical work, all […]

Updated EVIDENT database

The Evidence database on new technologies (EVIDENT Database) stores information on assessment, coverage and recommendations/requests for additional studies arising from HTA reports for promising technologies in Europe. Access is currently restricted to EUnetHTA Partners and Associates. The database was developed by HAS during Joint Action 1. Two upgraded database versions have been released during JA2 […]

Submission template for Pharmaceuticals and Submission template for Medical Devices

The EUnetHTA evidence submission template was developed from an analysis of evidence requirements for reimbursement in Europe. It is a tool that agencies can use to request evidence from companies to support their HTA and reimbursement processes. The tool covers relative effectiveness assessment including a description of the health condition and health technology, as well […]

EUnetHTA Position Paper on research recommendations for AEG

This document aims to help HTA authors/systematic reviewers define more specific recommendations for Additional Evidence Generation (AEG) – primary research arising from HTA. It provides a graphical approach for the identification of research gaps arising from HTA reports, and structures the formulation of subsequent research recommendations. Both real life uncertainties and those related to the […]

EUnetHTA Position Paper on study design for AEG

This document aims to help HTA authors/systematic reviewers define more specific recommendations for Additional Evidence Generation (AEG) – primary research arising from HTA. It discusses the role of the HTA author/systematic reviewer in specifying study design for AEG, contains an overview of EUnetHTA partners’ practices, and provides consideration of various issues around designing primary research […]

EUnetHTA Core protocol Pilot for AEG

This document consists of two parts: Methodological part (section 1), containing the template of Core protocol for AEG. This template defines which protocol items are essential to set up a common or coordinated AEG study (“core” items) and contains advice on how to fill them-in. First EUnetHTA pilot of a joint AEG recommendation (section 2). […]

WP7 SG2 Position paper on how to decide on the appropriate study design for AEG available

WP7 Subgroup 2 is pleased to announce the publication of the Position paper on how to decide on the appropriate study design for primary research arising from HTA reports. This document is one of two WP7 SG2 methodological documents aiming to help HTA authors/systematic reviewers in defining their recommendations for Additional Evidence Generation (AEG). This […]

WP7 SG2 Position paper on how to best formulate research recommendations for AEG

This document is one of two WP7 SG2 methodological documents aiming to help HTA authors/systematic reviewers in defining their recommendations for Additional Evidence Generation (AEG). It is focusing on providing a structured approach for the identification of research gaps and improving the presentation of research recommendations arising from HTA reports. Both uncertainties related to the […]

WP7-SG3 “Therapeutic medical devices” guideline

This guideline on “Therapeutic medical devices”, with answered comments from the SAG / Public consultation, is the last guideline of WP7 Subgroup 3 in JA2. Comments_answers_GL_Ther_medical_devices Therapeutic medical devices_Guideline_Final Nov 2015

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.